Accessibility Statement Skip Navigation
  • Resources
  • Data Privacy
  • Contact Us
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • All Multimedia

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Accessories
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High-Tech Security
        • Internet Technology
        • Nanotechnology
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Projections or Forecasts
        • Financing Agreements
        • Insurance
        • Joint Ventures
        • Mutual Funds
        • Offerings
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing/marketing agreements
        • New Products & Services
        • Obituary
        • Outsourcing Businesses
        • Overseas Real Estate (Non-US)
        • Personnel Announcements
        • Residential Real Estate
        • Small-Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Accessories
        • Computer Electronics
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Design Automation
        • Financial Technology
        • Mobile Devices/Apps
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Natural Gas Utilities
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Computer Accessories
        • Computer Networks
        • Mobile Devices/Apps
        • Telecommunications
        • Telecommunications Carriers & Services
        • Telecommunications Equipment
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wine & Spirits
        • Beverages
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infectious Disease Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental Products & Services
        • European Government
        • Natural Disasters
        • Not-for-Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Children-related news
        • Disabled Persons
        • Diversity, Equity & Inclusion
        • Hispanic-oriented news
        • LGBTQ+
        • Religion
        • Senior Citizens
        • Veterans
        • Women-Related news
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Request a Demo
    • Partnerships
    • Media Inquiries
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring Home
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us


    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • News Releases
      • Send a Release
      • Data Privacy
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • News Releases
      • Send a Release
      • Data Privacy
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • News Releases
      • Send a Release
      • Data Privacy
      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries
      • Editorial Bureaus
      • News Releases
      • Send a Release
      • Data Privacy
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • All Multimedia
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Everest Medicines Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD

      • APAC - Traditional Chinese

      News provided by

      Everest Medicines

      20 Nov, 2026, 13:00 CST

      Share this article

      Share this article


      SHANGHAI, Nov. 20, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, announced that the first patient has been treated in the ASCEND study, a randomized Phase 2b trial evaluating two doses of VIS-101 (6 mg and 9 mg) head-to-head against 2 mg aflibercept in approximately 244 treatment-naïve patients with wet age-related macular degeneration (wet AMD). The study is being conducted in China in partnership with Visara, Inc., a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, Inc. (NASDAQ: NBP).

      ASCEND's primary efficacy endpoint is the change in best-corrected visual acuity (BCVA) from baseline to Week 36 versus aflibercept dosed every eight weeks. The goal of the ASCEND study is to determine the dose(s) to advance into VIS-101's global Phase 3 program based on safety, efficacy and durability.

      VIS-101 is a purpose-designed tetravalent, dual VEGF-A x ANG-2 inhibitor in development for retinal vascular diseases, including wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO). In the randomized, dose ranging Phase 2a study, VIS-101 demonstrated rapid, robust, and durable treatment responses in wet AMD, along with a favorable safety profile. Approximately 50% of patients in the 6 mg treatment-naïve cohort remained retreatment-free six months after the last loading dose.

      Wet AMD affects more than 20 million people globally[1]. In China, the prevalent patient population of AMD and DME exceeds 15 million, with around 600,000 new cases each year, yet only about 500,000 patients currently receive treatment.

      "Patients with wet AMD and other retinal vascular diseases have significant unmet needs, as treatment burden remains a meaningful challenge for both patients and physicians," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "Dosing the first patient in the Phase 2b ASCEND study marks an important step in the clinical development of VIS-101. With encouraging efficacy, safety and durability results observed in Phase 2a, we believe VIS-101 has the potential to offer longer intervals between injections and sustained disease control. ASCEND will further evaluate this potential against an established standard of care, with findings supporting future global development.

      Our established clinical and commercial capabilities across China and other Asian markets will enable us to accelerate efforts to bring VIS-101 to patients and make this innovative therapy available to more patients."

      On October 30, 2025, Everest Medicines entered into a collaboration agreement with Visara, under which Everest acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries.

      About the ASCEND Phase 2b Trial

      ASCEND is a randomized, quadruple-masked, active-controlled, head-to-head Phase 2b study (NCT07798375) to evaluate the safety and efficacy of VIS-101 (aka AM712 or ASKG712) in approximately 244 treatment naïve patients with wet AMD in China. Patients will be randomized to either 6 mg or 9 mg VIS-101, or 2 mg aflibercept, a standard-of-care anti-VEGF therapy. All patients will initially receive three monthly doses of either VIS-101 or aflibercept and can then be retreated based on protocol-specified retreatment criteria that are the same for all groups up to Month 9. The main objectives are to determine the dose(s) to be studied in Phase 3 clinical trials and establish the initial durability with treatment intervals up to seven months after three loading doses.

      About VIS-101

      VIS-101 (also known as ASKG712 or AM712), is a dual VEGF-A X ANG-2 inhibitor in development for the treatment of retinal vascular diseases, such as wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO). VIS-101's bispecific, tetravalent design format provides more binding sites and increased VEGF-A and ANG-2 affinity and avidity, for rapid, robust and durable responses. VIS-101 has completed initial safety and dose-escalation studies in both the US and China and a randomized, dose-ranging 2a study in China (NCT05456828). VIS-101 is currently being evaluated in the dose-determining Phase 2b ASCEND study, with initiation of the global Phase 3 program planned as early as 2027.

      About Everest Medicines

      Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company owns a global manufacturing base of commercial scale in Jiashan, Zhejiang Province, and has established a comprehensive GMP production quality management system in accordance with China, EU, and WHO standards.

      The Company's therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Its pharmaceutical distribution capabilities further complement its existing manufacturing and commercialization operations, supporting efficient product supply and delivery to the market.

      Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion.

      For more information, please visit the Company's website: www.everestmedicines.com. 

      Forward-Looking Statements

      This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

      Source information:

      1. Invest Ophthalmol Vis Sci. 2021 Nov 24; 62 (14): 26. doi: 10.1167/iovs.62.14.26

      SOURCE Everest Medicines

      Modal title

      Also from this source

      Everest Medicines Announces Inclusion of VELSIPITY® and XERAVA® in China's 2026 National Reimbursement Drug List

      Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development,...

      Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development

      Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development,...

      More Releases From This Source

      Explore

      Pharmaceuticals

      Pharmaceuticals

      Biotechnology

      Biotechnology

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      News Releases in Similar Topics

      Contact PR Newswire

      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Become a Publishing Partner
      • Careers
      • Accessibility Statement
      • APAC – Simplified Chinese
      • APAC
      • APAC - Traditional Chinese
      • Arabic
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States
      • Vietnam

      My Services

      • All New Releases
      • Platform

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      [email protected]
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      • Accessibility
      Copyright © 2026 Cision US Inc.